Sonic hedgehog is expressed in human brain arteriovenous malformations and induces arteriovenous malformations in vivo by Giarretta, I. (ORCID:0000-0001-5380-0843) et al.
Original Article
Sonic hedgehog is expressed in human
brain arteriovenous malformations and
induces arteriovenous malformations
in vivo
Igor Giarretta1, Carmelo L Sturiale2, Ilaria Gatto1,
Simone Pacioni2, Eleonora Gaetani1, Angelo Porfidia1,
Alfredo Puca2, Ivana Palucci3, Paolo Tondi1, Alessandro Olivi2,
Roberto Pallini2 and Roberto Pola1,4
Abstract
Abnormalities in arterial versus venous endothelial cell identity and dysregulation of angiogenesis are deemed important
in the pathophysiology of brain arteriovenous malformations (AVMs). The Sonic hedgehog (Shh) pathway is crucial for
both angiogenesis and arterial versus venous differentiation of endothelial cells, through its dual role on the vascular
endothelial growth factor/Notch signaling and the nuclear orphan receptor COUP-TFII. In this study, we show that Shh,
Gli1 (the main transcription factor of the Shh pathway), and COUP-TFII (a target of the non-canonical Shh pathway) are
aberrantly expressed in human brain AVMs. We also show that implantation of pellets containing Shh in the cornea of
Efnb2/LacZ mice induces growth of distinct arteries and veins, interconnected by complex sets of arteriovenous shunts,
without an interposed capillary bed, as seen in AVMs. We also demonstrate that injection in the rat brain of a plasmid
containing the human Shh gene induces the growth of tangles of tortuous and dilated vessels, in part positive and in part
negative for the arterial marker aSMA, with direct connections between aSMA-positive and -negative vessels. In sum-
mary, we show that the Shh pathway is active in human brain AVMs and that Shh-induced angiogenesis has characteristics
reminiscent of those seen in AVMs in humans.
Keywords
Arteriovenous malformation, Sonic hedgehog, angiogenesis, VEGF, growth factors
Received 10 September 2019; Revised 18 February 2020; Accepted 19 February 2020
Introduction
Brain arteriovenous malformations (AVMs) are abnor-
malities of the intracranial vessels, with direct connec-
tions between the arterial and venous systems in the
absence of an intervening capillary bed. AVMs can
reach considerable size and undergo rupture and are
the main non-traumatic cause of cerebral hemorrhage
in young people.1
Etiology and pathogenesis of brain AVMs remain
poorly understood, hindering the development of effi-
cacious therapeutic strategies. Current theories propose
that abnormalities in arterial versus venous identity of
endothelial cells (ECs) are important for AVM forma-
tion. Indeed, AVM nidi co-express both arterial and
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venous markers, suggesting that AVMs consist of ves-
sels that have undergone inadequate maturation and
are not terminally differentiated.2 Nonetheless, it is
known that AVMs can form de novo during childhood
and/or adulthood as result of aberrant angiogenesis,
arteriogenesis, and vasculogenesis.3–6
The Sonic hedgehog (Shh) signaling pathway is cru-
cial for arterial versus venous differentiation of ECs.7
Studies in zebrafish have shown that embryos lacking
Shh fail to express vascular endothelial growth factor
(VEGF) within the somites and are unable to establish
arterial identity in the dorsal aorta.8 Conversely, micro-
injection of messenger RNA encoding Shh in zebrafish
embryos leads to a switch from a venous to an arterial
fate in the posterior cardinal vein.8 It is now accepted
that Shh regulates VEGF expression and acts upstream
of Notch to induce arterial differentiation of ECs also
in mammals and in postnatal life.8,9 VEGF induction
by Shh occurs through the activation of the canonical
Shh signaling pathway, with the involvement of the
glioma-associated oncogene homolog (GLI) family of
transcription factors.10 On the other hand, Shh has also
the ability to activate COUP-TFII, through a GLI-
independent non-canonical mechanism, since the
COUP-TFII promoter contains a Shh response element
that mediates Shh-induced activity.11 Importantly,
COUP-TFII is a down-regulator of Notch and is spe-
cifically expressed in venous, but not arterial,
endothelium.12
Shh is also a major regulator of angiogenesis, arte-
riogenesis, and vasculogenesis and has the ability to
upregulate various families of angiogenic growth fac-
tors, including three different isoforms of VEGF-A,
VEGF-D, angiopoietins, insulin-like growth factor-1,
fibroblast growth factor , and stromal-derived factor-
1a.13–16 Interestingly, Shh-induced angiogenesis has a
distinctive morphology characterized by enlarged and
apparently poorly organized tubular structures.13
In this study, we evaluated the expression of Shh, its
main transcription factor Gli1, and its non-canonical
target COUP-TFII, in human brain AVMs. We also
tested the hypothesis that Shh has the ability to
induce the formation of AVMs in vivo.
Materials and methods
The data that support the findings of this study are
available from the corresponding author upon reason-
able request.
Shh pathway expression in human brain AVMs
Analyses were performed on eight archival paraffin-
embedded specimens of human brain AVMs surgically
treated at the Institute of Neurosurgery, Universita`
Cattolica del Sacro Cuore of Rome, Italy. Specimens
of pediatric patients and patients with hereditary hem-
orrhagic telangiectasia were excluded from the study.
Archival paraffin-embedded specimens of human brain
derived from epilepsy surgery (n¼ 5) were used as con-
trols. The clinical characteristics of patients and con-
trols are available in the Supplementary Tables 1 and 2.
Primary antibodies were: rabbit polyclonal anti-Shh,
anti-Gli1, and anti-COUP-TFII (Origene, Rockville,
MD, USA). Secondary antibody was CFR
Antipolivalent HRP Polymer (Scytec Laboratories,
Logan, UT, USA). Protein expression was visualized
using the avidin–biotin–peroxidase complex method
(Dako AutoStainer, Carpinteria, CA, USA).
Specimens of human kidney cancer, brain, and tonsil
were used as positive controls for Shh, Gli1, and
COUP-TFII, respectively. The study was in compliance
with the Declaration of Helsinki and was approved by
the Ethics Committee of the Universita` Cattolica del
Sacro Cuore, Rome, Italy. Due to the nature of the
study, which only used archival specimens, informed
consent from patients was not needed.
Shh-induced angiogenesis in murine cornea
Efnb2/LacZ heterozygous mice (8–12weeks of age)
(n¼ 18) (Jackson Laboratories, Bar Harbor, ME,
USA) were used for these experiments. These mice
carry a non-disruptive insertion of the LacZ reporter
gene under the control of the Efnb2 promoter. LacZ
expression corresponds to Efnb2 expression and, since
Efnb2 is exclusively expressed in the arterial endotheli-
um and is absent in the venous endothelium, allows
distinguishing between arteries and veins.17 Corneal
micropockets were created as described.13,18,19 Pellets
containing Shh 0.5lg, VEGF 0.5mg, or PBS (empty
pellets) were implanted in corneal micropockets.
A total of 18 mice were used and, in each animal,
both corneas were used, in order to have 12 corneas
implanted with Shh pellets, 12 corneas implanted with
VEGF pellets, and 12 corneas implanted with PBS pel-
lets. Corneas were assigned randomly to each group of
pellets. Six days later, mice were euthanized, eyes were
enucleated, fixed, and used for whole mount immuno-
fluorescent (six corneas per group) or histochemical
analyses (six corneas per group). For immunofluores-
cent studies, corneal hemispheres were prepared under
a dissecting microscope and incubated with anti-CD31
(BD Pharmingen, Franklin Lakes, NJ, USA) and anti-
b-gal antibodies (Abcam, Cambridge, UK). FITC and/
or Cy3-conjugated secondary antibodies (Thermo
Fisher Scientific, Waltham, MA, USA) were used for
fluorescent detection. For histochemical staining, cor-
neas were embedded in paraffin, cut in cross-sections,
and stained using the same anti-mouse CD31 antibody
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described above followed by a biotinylated goat anti-
rabbit immunoglobulin secondary antibody (Abcam,
Cambridge, UK). X-gal staining was performed as
established.20 Corneal angiogenesis was quantified as
described previously.13,18,19 Briefly, for each cornea, a
minimum of five sections were observed under the
microscope, in order to assess vessel length, circumfer-
ential extent of neovascularity, lumen diameter, arter-
ies/veins ratio, mean length and diameter of arteries,
and mean length and diameter of veins. All quantifica-
tions were performed in a blinded fashion. The experi-
ments were conducted at the Division of
Cardiovascular Research of St. Elizabeth’s Medical
Center, Boston, MA, in accordance with the
American Association for the Accreditation of
Laboratory Animal Care (AAALAC) policies and
were approved by the Ethics Committee of the St.
Elizabeth’s Medical Center. Results are reported in
compliance with the ARRIVE (Animal Research:
Reporting in Vivo Experiments) guidelines.
Shh-induced angiogenesis in rat brain
To test whether the activation of the Hegdhog (Hh)
pathway in the brain induces angiogenic growth remi-
niscent of AVM, we used the plasmid human Shh
(phShh), which is a pCMV-Script vector containing
the human Shh cDNA that we have used previously
to induce functional activation of the Hh pathway in
experimental models of myocardial ischemia and
peripheral limb ischemia in mice, rats, and pigs.21–24
The animals used for these experiments were Wistar
rats (average weight 250 g). They received an intracere-
bral injection of 300 mg phShh, resuspended in 50 ml
PBS. The amount of phShh to be injected was calculated
on the basis of the relative mass of brain compared to
heart and skeletal muscle in rats and the dose of phShh
that we used in our previous experiments.21–24 The
injections were performed under general anesthesia, as
follows: animal skulls were immobilized in a stereotactic
head frame, a burr hole was made 2mm right of the
midline and 1mm anterior to the coronal suture, and
the solution containing the phShh was slowly injected
using the tip of a 100-ml Hamilton microsyringe placed
at a depth of 5mm from the dura. The injection of
phShh was performed unilaterally in the right brain
hemisphere. Injection of empty plasmid (300 mg) was
performed in the left hemispheres of the same rat
brains, which served as internal controls. This procedure
has been described previously and allows the operator to
selectively inject the plasmid at the level of the corpus
striatum.25,26 A total of five rats were used. The
calculation of the sample size was based on an estimated
incidence of AVMs of 90% in rat brain hemispheres
injected with phShh and of 10% in hemispheres
injected with the empty plasmid. To achieve 80%
power at the 5% significance level, we calculated a
required sample size of at least five rats per group. In
compliance with the 3R principles – Replace, Reduce
and Refine – for the ethical use of animals in medicine
testing, both cerebral hemispheres of each animal were
used (the right hemisphere for the injection of phShh
and the left hemisphere for the injection of the empty
plasmid).
After the intracerebral injections, animals were kept
under pathogen-free conditions in positive-pressure
cabinets (Tecniplast Gazzada, Varese, Italy) and
observed daily for neurological signs. Body weight
was monitored weekly. Two weeks after injection,
rats were deeply anesthetized and transcardially per-
fused with 0.1M PBS (pH 7.4), then treated with 4%
paraformaldehyde in 0.1M PBS. Brains were removed,
stored, serially cryostat sectioned, and used for immu-
nodetection of CD31, using a polyclonal mouse anti-
CD31 antibody (BD Bioscience, Franklin Lakes, NJ,
USA), and a-smooth muscle actin (aSMA), using a
polyclonal goat anti-aSMA antibody (Abcam,
Cambridge, UK). Secondary antibodies were: Alexa
Fluor 647 donkey anti-mouse (1:500) (Abcam,
Cambridge, UK) and Cy3 donkey anti-goat (1:200)
(EMD Millipore, Billerica, MA, USA). For the detec-
tion of COUP-TFII expression in brain vasculature,
sections were incubated with lectin from Lycopersicon
esculentum (tomato) biotin conjugate (1:500) (Sigma-
Aldrich, St. Louis, MO, USA) together with a rabbit
polyclonal anti-COUP-TFII antibody (Origene,
Rockville, MD, USA). The secondary antibody for
the detection of COUP-TFII was an Alexa Fluor 647
donkey anti-rabbit (1:100) (Abcam, Cambridge, UK).
Before mounting, slices were incubated with phosphate
buffer containing 40,6-diamidino-2-phenylindole
(DAPI) (1:4000) (Sigma-Aldrich, St. Louis, MO,
USA). For each rat hemisphere, a minimum of five
brain sections were observed under a laser confocal
microscope (SP5, Leica, Wetzlar. Germany). The
number of aSMA-positive and aSMA-negative vessels,
the mean lumen diameter of aSMA-positive and
aSMA-negative vessels, and the number of CD31-
positive vessels in the area surrounding the neovascular
tangle were assessed using a dedicated Leica
Application Suite X software. The analysis of histolog-
ical sections was performed in a blinded fashion by two
independent operators unaware of the specimen origin.
To determine which brain cells were transfected by
our plasmid, we inserted the DsRedCherry reporter
gene in the pCMV-Script plasmid, upon removal of
the Shh gene sequence using the BamHI-NotI restric-
tion enzyme (New England Biolab, Beverly, MA,
USA). Then, the pCMV-DsRedCherry (300 mg) was
injected in the left brain hemisphere of four Wistar
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rats, using the same stereotactic methodology described
above. Two weeks later, rats were sacrificed and brains
were harvested, stored, serially cryostat sectioned, and
processed for mCherry detection using a laser confocal
microscope (SP5, Leica, Wetzlar, Germany). To deter-
mine whether mCherry was expressed in astrocytes or
neuronal cells, brain sections were incubated with a
polyclonal rabbit anti-Glial Fibrillary Acidic Protein
(GFAP) (1:1000; Dako-Agilent, Santa Clara, CA,
USA) or a polyclonal rabbit Synaptophysin antibody
(1:250; Invitrogen Corporation, Carlsbad, CA, USA),
using the same protocols described above. Slices were
then incubated with Alexa Fluor 488-conjugated
donkey anti rabbit secondary antibodies (1:400;
Thermo Fisher Scientific, Waltham, MA).
The experiments were performed at the Universita`
Cattolica del Sacro Cuore, Rome, Italy, according to
the Directive 2010/63/EU of the European Parliament
and of the Council of 22 September 2010 on the pro-
tection of animals used for scientific purposes and were
approved by the Ethics Committee of the Fondazione
Policlinico Universitario A. Gemelli IRCCS. Results
are reported in compliance with the ARRIVE
(Animal Research: Reporting in Vivo Experiments)
guidelines.
Statistical analysis
All results are reported as mean SD. Differences
between groups were analyzed by paired t-test and con-
sidered statistically significant for P< 0.05.
Calculations were performed with Prism 7 (GraphPad
Software; www.graphpad.com/scientific-software/
prism/) and IBM SPSS Statistics for windows,
Version 20.0, released 2011 (IBM Corp; www.ibm.
com/analytics/it/it/technology/spss/).
Results
Aberrant expression of Shh signaling in human
brain AVMs
The results of immunohistochemical analysis of surgi-
cally resected human brain AVMs, compared to
normal human brain, are presented in Figure 1. We
found distinct Shh expression in the endothelial layer
of the AVM vessels. Also Gli1 was expressed in the
endothelium of human brain AVMs. COUP-TFII
was expressed both in the endothelium and the vascular
wall of the human brain AVMs that we analyzed. No
Shh, Gli1, or COUP-TFII-positive staining was found
in normal human brain vessels.
Shh-induced angiogenesis has AVM-like features
in vivo
The morphology of neoangiogenesis induced by Shh
was strikingly different from that induced by VEGF
in the murine cornea. In particular, Shh-induced neo-
vasculature consisted of large, branching vessels that
grew directly from the limbus vessels and extended to
and surrounded the pellet at the apex of the new vessel
growth (Figure 2(a)). In contrast, VEGF-induced
angiogenesis mainly consisted of shorter vessels
(unable to reach the pellet), uniform in size and
length, distributed along the corneal circumference in
Figure 1. Immunohistochemical analysis of Shh pathway expression in human brain AVMs. Representative images of human brain
AVMs and control brain vessels. Cells in the intimal layer of AVMs are strongly immunopositive for Shh and Gli1. COUP-TFII
immunopositive cells are detectable in the intimal and medial layers of AVMs. Control brain vessels are negative in terms of Shh, Gli1,
and COUP-TFII expression.
Shh: Sonic hedgehog.
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an orderly fashion (Figure 2(b)). In the setting of Shh-
induced neonagiogenesis, it was possible to identify
Efnb2-positive vessels originating directly from the
main limbus artery, as well as Efnb2-negative vessels
directly connected to the main limbus vein (Figure 2
(a)). In contrast, VEGF-induced angiogenesis mainly
consisted of Efnb2-positive vessels (Figure 2(b)).
Histological analysis of corneal cross sections con-
firmed the concomitant presence of arteries and veins
in the setting of Shh-induced corneal angiogenesis
(Figure 2(c)). Importantly, many Shh-induced vessels
exhibited branching and created complex vascular
trees with direct connections between arteries and
veins, without the presence of an interposed capillary
bed, as seen in AVMs (Figure 2(d)).
Corneal angiogenesis induced by Shh and VEGF
was quantified in terms of vessel length, circumferential
extent of neovascularity, lumen diameter, and arteries/
veins ratio (Figure 3(a)). The average length of
Shh-induced neovessels was significantly greater than
that of VEGF-induced vessels (1.2 0.3 versus
0.6 0.1mm; P< 0.0001). Increased lumen diameter
was also seen in Shh- versus VEGF-induced neovessels
(32.1 5.5 versus 7.8 1.5mm; P< 0.0001). Also the
circumferential extent of Shh-induced neovasculature
was increased compared with VEGF (184.2 2.8
Figure 2. Characterization of the arterial and venous pheno-
type of Shh-induced corneal neovessels. (a) When pellets con-
taining Shh are implanted in the corneal of Efnb2/LacZ mice, the
resulting angiogenic process consists of large Efnb2-positive
arterial vessels (red/yellow staining) that grow directly from the
main limbus artery toward the pellet and large and tortuous
Efnb2-negative, CD31-positive veins (green staining) directly
connected to the main limbus vein. (b) When pellets containing
VEGF are implanted in the cornea of Efnb2/LacZ mice, the
resulting angiogenic process consists of short Efnb2-positive
arterial vessels (red/yellow staining) that grow directly from the
main limbus artery and are orderly distributed along the corneal
circumference. (c) X-gal staining of the corneas of Efnb2/LacZ
mice implanted with Shh-containing pellets shows the concomi-
tant presence of X-gal positive arteries (blue staining) and X-gal
negative veins. (d) In the corneas of Efnb2/LacZ mice, Shh-
induced angiogenesis is characterized by the presence of direct
connections (white arrowheads) between Efnb2-positive arteries
(red/yellow staining) and Efnb2-negative, CD31-positive veins
(green staining).
Figure 3. Quantification and characterization of Shh- and
VEGF-induced corneal angiogenesis. (a) Vessel length
(P< 0.0001), lumen diameter (P< 0.0001), and circumferential
extent of neovascularity (P< 0.001) are significantly greater in
Shh rather than VEGF-induced corneal angiogenesis, while the
ratio between arteries and veins is greater in VEGF-induced
angiogenesis compared to Shh-induced angiogenesis (P< 0.01).
(b) In the setting of Shh-induced corneal angiogenesis, veins are
significantly longer than arteries (P< 0.01) and have a significantly
greater lumen diameter compared to arteries (P< 0.001).
Shh: Sonic hedgehog; VEGF: vascular endothelial growth factor.
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versus 121.1 8.7 degrees; P< 0.001). The arteries/
veins ratio was 0.7 0.1 and 1.6 0.3 in Shh- and
VEGF-induced angiogenesis, respectively (P< 0.01).
We also quantified mean length and diameter of arteries
and veins in the context of Shh-induced angiogenesis
(Figure 3(b)). Arteries and veins had a mean length of
0.9 0.1 and 1.5 0.2mm, respectively (P< 0.01). Mean
lumen diameter was 20.5 2.3 and 41.3 4.2mm for
arteries and veins, respectively (P< 0.001).
Shh-induced angiogenesis has AVM-like features
in the brain
A tangle of enlarged and tortuous vessels was found at
the site of injection in brain hemispheres treated with
phShh, while no visible changes were found in the vas-
culature of contralateral brain hemispheres injected
with the empty plasmid (Figure 4).
Some of these vessels were strongly positive for
aSMA, while others were clearly aSMA negative
(Figure 5(a)). Such heterogeneous aSMA positivity
suggests that these vessels are phenotypically different
and that aSMA-positive vessels are more likely to be
arteries, while aSMA-negative vessels are more likely to
be veins. Digital analysis demonstrated that
41.1 11.0% of the vessels forming the vascular
tangles found in the five brain hemispheres injected
with the phShh were positive for aSMA, while the
remaining vessels were aSMA negative (Figure 5(b)).
Quantitative analyses were performed to assess the
mean lumen diameter of aSMA-positive and -negative
vessels: it was 67.5 14.5 mm among aSMA-positive
vessels and 70.5 15.5 mm among aSMA-negative
vessels, substantially greater than the size of
surrounding brain microvasculature (Figure 5(c)).
In many histological sections, it was possible to iden-
tify aSMA-positive vessels directly connected to aSMA-
negative vessels, which suggests the existence of direct
arteriovenous communications in the setting of Shh-
induced angiogenesis in the brain (Figure 6(a)).
Interestingly, there was rarefaction of the brain vascula-
ture in the area surrounding the neoangiogenic tangle,
compared to the same brain area in the contralateral
hemisphere (Figure 6(b)), suggesting that the arteriove-
nous structures grown in response to phShh injection
might have hemodynamic effects on the surrounding
brain vasculature, similar to the blood flow alterations
seen in the presence of a ‘steal phenomenon’.
We looked for COUP-TFII expression in the
context of phShh-induced brain neovasculature, in
comparison with COUP-TFII expression in the contra-
lateral brain hemisphere. We found that the large ves-
sels that characterize phShh-induced brain
angiogenesis contain several COUP-TFII-positive
cells, both at the level of the endothelial layer and the
vascular wall (Figure 7(a)). In contrast, the vasculature
of the brain hemispheres that were injected with the
empty plasmid was virtually negative for COUP-TFII
expression (Figure 7(b)).
The histological analysis of brains injected with
pCMV-DsRedCherry revealed the presence of
mCherry fluorescence along the track of the needle
and around the injection site. There was also
mCherry-positive fluorescence within the wall layers
and around vascular structures. Some mCherry-
positive cells were positive for GFAP, indicating that
some astrocytes had been infected by the plasmid. No
mCherry-positive fluorescence was found in neurons.
These results are shown in Supplementary Figure 1.
Discussion
Our study presents several new findings. First, it shows
for the first time that the Shh pathway is active in
Figure 4. Effects of phShh injection in rat brain. In five rats, one
brain hemisphere was treated with an intracerebral injection of
phShh, while the contralateral hemisphere received an injection
of empty plasmid. A robust neoangiogenic process developed in
the hemispheres injected with phShh (right panels, 5, 10, and
20 magnification), while no changes were observed in the
vascularization of the brain hemisphere treated with the empty
plasmid (left panels, 5, 10, and 20 magnification).
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human brain AVMs. Second, it provides evidence that
Shh has the ability to stimulate the growth of an
ensemble of arteries and veins in vivo, with many
direct arteriovenous connections. Third, it demon-
strates that intracerebral injection of Shh results in
the generation of tangles of vessels that have many
characteristics that are strongly reminiscent of those
displayed by brain AVMs. Taken together, these data
identify Shh as a novel potential player in the patho-
genesis of AVMs.
Regarding our analysis of the human brain AVM
samples, it is important to point out that all the speci-
mens that we analyzed exhibited vessels that were
strongly immunopositive for the Shh ligand, as well
the proteins Gli1, which is the main transcription
factor of the canonical Shh pathway, and COUP-
TFII, which is a target of the non-canonical Shh
pathway, although there were many phenotypical
differences among the patients from whom the AVMs
were obtained, in terms of age, gender, AVM location,
size of the nidus, Martin-Spetzler grading, history of
bleeding, and presence of seizures (as shown in
Supplementary Table 1). In contrast, the control
brain specimens were all consistently negative for
Shh, Gli1, and COUP-TFII expression, despite the
fact that also these specimens were from phenotypically
different patients who had undergone epilepsy surgery
(as shown in Supplementary Table 2). The activation of
the Gli1-dependent canonical pathway is known to be
responsible for the upregulation of VEGF by Shh,
which eventually leads to the activation of Notch and
the determination of an arterial phenotype in ECs. On
the other hand, the activation of COUP-TFII by Shh is
known to lead to the downregulation of Notch, with
the consequent determination of a venous phenotype in
ECs. This is consistent with the recent demonstration
that ECs of human brain AVMs co-express both arte-
rial and venous markers, as they consist of not termi-
nally differentiated vessels.2 While the presence of
COUP-TFII in human brain AVMs has been shown
previously,2,27 ours is the first demonstration that Shh
and Gli1 are aberrantly expressed in the endothelial
Figure 5. Presence of aSMA-positive and aSMA-negative vessels in the context of Shh-induced brain neoangiogenesis. (a) Sections of
brain hemispheres treated with phShh were stained for CD31 and aSMA. In the context of phShh-induced brain neoangiogenesis, it
was possible to distinguish vessels that were aSMA-positive (red/yellow staining) and vessels that were aSMA-negative (green
staining). (b) Quantification of the percentage of aSMA-positive and aSMA-negative vessels within the vascular tangles grown in
response to phShh intracerebral injection. (c) Quantification of the mean lumen diameter of aSMA-positive and aSMA-negative vessels
within the vascular tangles grown in response to phShh intracerebral injection.
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layer of human brain AVMs. Indeed, there is only one
report that has analyzed the expression levels of vari-
ous components of the Hh pathways in brain AVMs,
finding heterogeneous expression of various Hh ligands
and the Hh receptor Patched-1 across the AVMs that
were analyzed, without conclusive results.27 However,
in such report, the Hh pathway was only collaterally
investigated, as the study was focused on COUP-TFII
and other molecules involved in venous and lymphatic
signaling. In addition, the analysis of the Hh pathway
was performed only by quantitative real-time polymer-
ase chain reaction on total mRNA extracted from
whole AVM specimens, without any histological exam-
ination. Since, as indicated by our results, Shh and Gli1
are specifically expressed in ECs, and ECs constitute
only 1–2% of the total cells in cerebral AVMs,28 the
analysis of total mRNA obtained from whole AVM
specimens is likely to underestimate the expression
levels of genes involved in Hh signaling in ECs.
Analysis of gene expression at the single EC level, or
upon isolation of ECs from human brain AVMs,
would be necessary to overcome this issue.
Regarding the results of our corneal model experi-
ments, they are consistent with our previous demon-
stration that Shh-induced neovasculature is different
from that induced by VEGF and consists of enlarged
and twisted vessels without an organized network.13
Compared to our previous publication, the novelty of
the present study is the analysis of the arterial versus
venous phenotype of Shh-induced corneal neovessels.
Indeed, in this study, we provide evidence that Shh has
the ability to stimulate the growth of an ensemble of
arteries and veins in vivo, with many direct arteriove-
nous connections. This finding is particularly relevant
because it has been replicated by us at the level of the
brain. The tangles of vessels grown in response to
phShh intracerebral injection have many characteristics
that are strongly reminiscent of those displayed by
brain AVMs: (i) vessels are tortuous and have a mac-
roscopically visible lumen, with a bigger caliber size
compared to normal cerebral microvessels; (ii) they
are partly positive and partly negative for aSMA,
which demonstrates that they are phenotypically het-
erogeneous; (iii) they exhibit numerous direct connec-
tions between aSMA-positive and aSMA-negative
vessels, which suggests the existence of arteriovenous
shunts; (iv) they contain COUP-TFII-positive cells. We
are aware that aSMA-positivity cannot be considered a
definite marker of arterial identity; however, it is a
matter of fact that some of the vessels contained in
Shh-induced tangles are positive for this marker,
while others are negative. This indicates that these ves-
sels do not have a homogeneous structure, but instead
have important phenotypical differences, as it occurs in
AVMs. In addition, there is reduced vascularization in
the brain area that surrounds phShh-induced angiogen-
esis, reminiscent of the steal phenomenon that occurs in
human brains in the presence of AVMs. This provides
further support to the hypothesis that Shh-induced vas-
cular tangles contain arteriovenous shunts. Finally, the
presence of COUP-TFII-positive cells in the context of
phShh-induced neovessels, and its absence in control
rat brains, is consistent with the findings of previous
studies that have demonstrated that COUP-TFII is
aberrantly expressed in the nidus of brain AVMs in
humans, while its expression is very low in the blood
vessels as well as the brain parenchyma of normal
tissues.2,25
The precise molecular mechanisms responsible for
the formation of AVM-like structures in response to
Shh injection remain to be elucidated. As outlined
above, a role might be certainly played by the dual
ability of Shh to regulate the expression of VEGF/
Notch and COUP-TFII, thus leading to the activation
of both arterial and venous determination pathways.
Nonetheless, the interplay between Hh, VEGF,
Notch, and COUP-TFII during arteriovenous specifi-
cation is extremely complex, and even the established
view of the cascade of Hh, VEGF, and Notch acting
instructively on ECs to control the choice between
arterial or venous fate has been challenged, as
Figure 6. Presence of direct arteriovenous connections in the
context of Shh-induced brain neoangiogenesis. (a)
Representative image of direct connections (white arrows)
between two aSMA-negative vessels (green staining) and one
aSMA-positive vessel (red/yellow staining) within phShh-induced
brain neoangiogenesis. (b) Rarefaction of the brain vasculature in
the area surrounding phShh-induced neoangiogenesis compared
to the same brain area in the contralateral hemisphere injected
with the empty plasmid.
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demonstrated by the fact that Hh may bypass
VEGF and use alternative pathways to induce arterial
differentiation in ECs.29 What we know is that the
Shh pathway is a highly preserved signal that acts
upstream of many crucial angiogenic mediators,
including those determining the arterial and venous
identity of ECs. Also, it is important to point out
that previous attempts to generate AVMs injecting
angiogenic growth factors in the brain of wild-type
animals have been unsuccessful. In particular,
VEGF has shown the ability to generate clusters of
twisted, dilated, and dysplastic microvessels with arte-
riovenous shunts, but only when injected in mouse
models genetically predisposed to AVMs, such as the
endoglin and ALK1-deficient mice.25,30–35 Different
from VEGF, injection of Shh in wild-type animals
has resulted in the growth of AVM-like vascular
anomalies.
Finally, it remains to be determined whether and
how activation of the Shh pathway may occur in the
adult brain. In this context, we have already demon-
strated that, in the heart and the skeletal muscle, ische-
mia induces strong overexpression of Shh.14,21
Additional experiments have shown that hypoxia per
se – independently on ischemia – is able to induce a
rapid and systemic Hh response in various organs of
adult mice, with the Hh response being preceded by the
accumulation of the master transcriptional regulator of
hypoxia HIF1a (hypoxia-inducible factor 1a).36,37
There is also evidence that the Shh signaling pathway
may be recapitulated in adult tissues in response to
chemical and mechanical injury.18,24,38–40 Based on
this, it might be speculated that the aberrant expression
of Shh that we have observed in human brain AVMs
might be the result of local and subclinical
hypoxic, ischemic, mechanical, and/or toxic stimuli.
Figure 7. Expression of COUP-TFII in phShh-induced brain neovessels. Sections of brain hemispheres injected with phShh and
empty plasmid were stained for DAPI (blue staining) to identify cell nuclei, lectin (red staining) to identify blood vessels, and COUP-
TFII (green staining) to identify cells expressing this vascular differentiation marker. (a) COUP-TFII-positive cells were found in the
neovessels grown in the brain in response to phShh injection, both at the level of the intimal layer and the vascular wall. (b) COUP-
TFII-positive cells were virtually absent in brain hemispheres injected with the empty plasmid.
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Nonetheless, at the moment, no clinical evidence exists
for any of these mechanisms in the pathogenesis of
brain AVMs. A further hypothesis is that, once an arte-
riovenous shunt is formed, the commixture of arterial
and venous blood may generate local hypoxia, accord-
ing to the concept of the steal phenomenon, with even-
tual further activation of the Hh pathway.
The poor understanding of the pathogenesis of brain
AVMs hinders the development of biological treat-
ments. It has been attempted to act on molecular path-
ways that are disrupted in brain AVMs, including
Notch and VEGF. Inhibitors of Notch have been
developed and have been found to be safe in clinical
trials on subjects affected by Alzheimer’s disease and
cancer.41 Therefore, they might represent a prospective
promising therapeutic approach for brain AVMs.
VEGF may be targeted using the humanized monoclo-
nal antibody bevacizumab, which has an established
safety profile and has been tested in a number of path-
ological conditions, including the brain cancer glioblas-
toma.42,43 There are also anecdotal reports on the use
of bevacizumab in subjects with brain AVMs.44–48
However, efficacy and safety of this therapy in
human brain AVMs remain to be determined, and a
phase I trial is currently enrolling adult patients with
high-grade AVMs (NCT02314377). Our findings sug-
gest the possibility to use anti-Shh treatments as novel
therapeutic approach for brain AVMs. There are Hh
pathway inhibitors that have been approved by the
Food and Drug Administration and are currently
used for the treatment of basal cell carcinoma and
acute promyelocytic leukemia.49–53 If our findings are
confirmed and the Hh pathway is found to be a rele-
vant player in the pathogenesis of brain AVMs, a role
for anti-Hh therapies in this field could be hypothe-
sized, with the theoretical possibility to deliver these
drugs both systemically or locally, through the selective
endovascular catheterization of the AVM feeders.
In conclusion, this study provides the first demon-
stration that the Shh pathway is active in human brain
AVMs. It also shows that the angio-architecture of
Shh-induced angiogenesis in vivo is strikingly reminis-
cent of that found in AVMs, with tortuous and dilated
arteries and veins and numerous direct arteriovenous
shunts. Notably, Shh has the ability to induce such
aberrant angiogenic process in the brain of wild-type
animals, thus in the absence of a genetic background
that could facilitate the development of AVMs. Our
findings might have several important implications,
both at the biological, clinical, and therapeutic levels.
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